← Back

Zhejiang Xianju Pharmaceutical Co Ltd

Zhejiang Xianju Pharmaceutical Co., Ltd. researches, develops, produces, and sells steroid raw materials and preparations in China and internationally. Its products include cortical steroids, gynecology and family planning drugs, respiratory and dermatological drugs, anaesthetics and muscle relaxants, as well as active pharmaceutical ingredients and intermediates. The company also provides contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO), technical, technology development, and inspection and testing services. Founded in 1972, it is headquartered in Xianju, China.

Price · split & dividend adjusted
News & notes moving 002332.CS
002332.CS▼

Xianju Pharmaceutical's 2026 interim net profit was 245 million yuan, down 20.67% year-on-year

Xianju Pharmaceutical released its 2026 interim report. Total operating revenue was 1.959 billion yuan, up 4.78% year-on-year, but net profit attributable to the parent was 245 million yuan, down 20.67% year-on-year. Net cash inflow from operating activities was 360 million yuan, an increase of 360 million yuan year-on-year. The asset-liability ratio was 15.23%, down 1.50 percentage points from the same period last year. Gross margin was 62.15%, down 1.01 percentage points from the same period last year. ROE was 4.10%, down 1.03 percentage points from the same period last year. Diluted earnings per share were 0.25 yuan, down 20.67% year-on-year.
002332.CS ▼
Jiemian·22dRead more →
002332.CS

Xianju Pharma's Three Products Tentatively Selected for the 12th National Drug Procurement

Zhejiang Xianju Pharmaceutical announced that its products drospirenone and ethinylestradiol tablets (II), dydrogesterone tablets, and betahistine mesilate tablets have been tentatively selected for the 12th National Centralized Drug Procurement. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. Drospirenone and ethinylestradiol tablets (II) had domestic sales of approximately 48.58 million yuan in 2025, accounting for 1.29% of revenue, and about 15.34 million yuan in the first quarter of 2026, representing 1.67%. Dydrogesterone tablets recorded sales of around 3.41 million yuan in 2025 and about 3.46 million yuan in the first quarter of 2026. Betahistine mesilate tablets were approved in May 2026 and have not yet generated sales. The company stated that medical institutions will prioritize the use of selected products and ensure the fulfillment of agreed procurement volumes, but subsequent developments and the impact on company performance remain uncertain.
002332.CS
Jiemian·47dRead more →
002332.CS▲3

Xianju Pharmaceutical's Hormonal Drug Ethinylestradiol Cyproterone Acetate Tablets Passes Consistency Evaluation

Xianju Pharmaceutical announced that its Ethinylestradiol Cyproterone Acetate Tablets have passed the generic drug quality and efficacy consistency evaluation, receiving the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. Each tablet contains 2 mg of cyproterone acetate and 0.035 mg of ethinylestradiol, indicated for the treatment of moderate to severe acne and/or hirsutism in women of reproductive age, especially those with polycystic ovary syndrome. In the first quarter of 2026, Xianju Pharmaceutical achieved revenue of 918 million yuan and a net profit attributable to the parent company of 93.89 million yuan.
002332.CS ▲
财中社·50dRead more →
© 2026 MarketDXAsset